ORGN vs VVOS vs JPM

For growth investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger pick with 16. 0% revenue growth year-over-year, versus -39. 5% for Origin Materials, Inc. (ORGN). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -99. 6% for Origin Materials, Inc. (ORGN). Over 10 years, the gap is even starker: JPM returned +481. 2% versus VVOS's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.

(VVOS) is the lower-risk stock at 0. 51β versus Origin Materials, Inc. 's 1. 54β — meaning ORGN is approximately 202% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Origin Materials, Inc. (ORGN) carries a lower debt/equity ratio of 27% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vivos Therapeutics, Inc.

(VVOS) is pulling ahead at 16. 0% versus -39. 5% for Origin Materials, Inc. (ORGN). On earnings-per-share growth, the picture is similar: Vivos Therapeutics, Inc. grew EPS 7. 2% year-over-year, compared to -188. 2% for Origin Materials, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -1319. 6% for Origin Materials, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -335. 4% for ORGN. At the gross margin level — before operating expenses — VVOS leads at 60. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ORGN: 8156.

9% to $90. 00.

In this comparison, JPM (1.

8% yield) pays a dividend. ORGN, VVOS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Origin Materials, Inc. (ORGN) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +481. 2%, ORGN: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ORGN (Basic Materials) and VVOS (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ORGN is a small-cap quality compounder stock; VVOS is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ORGN, VVOS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.